EisnerAmper’s Technology and Life Sciences practice talks about the Theranos dissolution, its investors, valuation and internal controls.

Lessons Learned from the Theranos Dissolution


A senior manager in EisnerAmper’s Technology and Life Sciences practice, talks about the rise and fall of Theranos. He explains what took them from biotech unicorn to dissolution, the fallout, and how companies and investors can mitigate risk. 


Dave Plaskow: Hello and welcome to the EisnerAmper Technology Podcast Series. With more than 500 technology clients, we're always interested in the latest industry trends and developments as well as any related business and accounting opportunities and challenges. I'm your host, Dave Plaskow, and with us today is a senior manager in EisnerAmper's Technology and Life Sciences practice. It's another episode of TechTalk. Today's episode is on some of the lessons learned from the Theranos dissolution. Welcome.
Dave Katz: Thank you, Dave. Good to be here.

John Pennett has public accounting experience with a strong emphasis on life sciences companies. Member New Jersey Society of Certified Public Accountants and New Jersey Technology Council and advisory board of eLabs.

Contact John

* Required